Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Reapplication of the Type IV Hypersensitivity Quantitative Risk Assessment to Assess Ingredients Used on Canines

McDermott A., Lorch G., Nash J., Kern P.

Narrative Review on Hair & Scalp, published in Vet Med Sci (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Vet Med Sci (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40536915
PMCID
PMC12178314
DOI
10.1002/vms3.70463

Abstract (original English)

A quantitative risk assessment (QRA) framework to assess the risk for the induction of human skin sensitization from exposure to contact allergens has been successfully developed and applied. So far, the QRA has not been applied in a canine risk assessment for establishing concentration limits of ingredients with Type IV hypersensitivity potential. Outlining this risk assessment is critical, as shampoos are known to cause allergic contact dermatitis (ACD) in canines. Additionally, humans have developed ACD after washing their dogs with dog shampoo. To address this gap, we conducted a thorough literature review on canine Type IV hypersensitivity and identified potential differences which might demand an adaptation of the QRA. We summarize data from the literature demonstrating that all four key events (KE) in the skin sensitization adverse outcome pathway (AOP) are present in dogs as they are in humans, guinea pigs, and mice. The hazard potential of sensitizers for canines is compared with the established sensitization QRA framework for humans. The limited collective evidence suggests that dogs are not more susceptible to sensitizers than humans; therefore, safety-defined concentration limits from Type IV hypersensitivity risk assessments for humans can be re-applied to canines so long as their unique exposure considerations are factored in. Using the principles in this review,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsDogsHumansDermatitis, Allergic ContactDog DiseasesAllergensHair PreparationsRisk Assessment

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research